Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-BMD in Refractory or Relapsed Follicular Lymphoma
NCT01133158Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Jul 2009
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies, Lipid-based Nanoparticles, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, bendamustine, mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells, dexamethasone in follicular lymphoma (FL), sponsored by GELTAMO. Started Jul 2009; status: completed.
02
Drugs
rituximabbendamustinemitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cellsdexamethasone
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01133158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01133158.